Report Summary:
HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer.
HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein.
HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine.
These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells. The report analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.
Covered in this report:
This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer.
Based on type of drug molecule, the market is segmented as follows:
HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer.
HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein.
HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine.
These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells. The report analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.
Covered in this report:
This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer.
Based on type of drug molecule, the market is segmented as follows:
- Biologics
- Small molecules
Based on route of administration, the market is segmented as follows:
- Oral
- Parenteral
To Read more reports of this category:
http://www.radiantinsights.com/catalog/pharmaceutical
This report includes a discussion of the market in the following three regions:
http://www.radiantinsights.com/catalog/pharmaceutical
This report includes a discussion of the market in the following three regions:
- Americas (the US, Canada, Mexico, and Brazil)
- EMEA (the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE)
- APAC (Japan, China, Australia, Singapore, South Korea, and India)
Global HER2-Negative Breast Cancer Market has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key region
Key region
- Americas
- APAC
- EMEA
Key vendors
- F. Hoffmann-La Roche
- Novartis
- Pfizer
Other prominent vendros
- AbbVie
- AstraZeneca
- BioMarin
- Bristol-Myers Squibb
- Eisai
- Eli Lilly
- Galena Biopharma
- Incyte
- Merck
- Merck Serono
- Merrimack
- Nektar
- Tesaro
Key market driver
- Significant unmet needs
- For a full, detailed list, view our report
Key market challenge
- Premium-priced therapies
- For a full, detailed list, view our report
Key market trend
- Emerging therapies
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
No comments:
Post a Comment